| Literature DB >> 26167193 |
Lara Gibellini1, Elena Bianchini2, Sara De Biasi1, Milena Nasi1, Andrea Cossarizza1, Marcello Pinti2.
Abstract
Mitochondria are organelles responsible for several crucial cell functions, including respiration, oxidative phosphorylation, and regulation of apoptosis; they are also the main intracellular source of reactive oxygen species (ROS). In the last years, a particular interest has been devoted to studying the effects on mitochondria of natural compounds of vegetal origin, quercetin (Qu), resveratrol (RSV), and curcumin (Cur) being the most studied molecules. All these natural compounds modulate mitochondrial functions by inhibiting organelle enzymes or metabolic pathways (such as oxidative phosphorylation), by altering the production of mitochondrial ROS and by modulating the activity of transcription factors which regulate the expression of mitochondrial proteins. While Qu displays both pro- and antioxidant activities, RSV and Cur are strong antioxidant, as they efficiently scavenge mitochondrial ROS and upregulate antioxidant transcriptional programmes in cells. All the three compounds display a proapoptotic activity, mediated by the capability to directly cause the release of cytochrome c from mitochondria or indirectly by upregulating the expression of proapoptotic proteins of Bcl-2 family and downregulating antiapoptotic proteins. Interestingly, these effects are particularly evident on proliferating cancer cells and can have important therapeutic implications.Entities:
Year: 2015 PMID: 26167193 PMCID: PMC4489008 DOI: 10.1155/2015/527209
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chemical structure of quercetin (Qu), resveratrol (RSV), and curcumin (Cur).
Direct and indirect effects of Qu, RSV, and Cur on mitochondrial ROS.
| Molecule | Effects on mitochondrial ROS | Model used | Doses | Time of treatment | References |
|---|---|---|---|---|---|
|
| |||||
| Direct effects | Scavenging of O2 ∙− | Cell-free system; CHO cells | 10–200 | Up to 24 hours | [ |
| Scavenging of H2O2 | Cell-free system; CHO cells | 10–200 | Up to 24 hours | [ | |
| Direct effects as prooxidant | Production of semiquinone radical and Qu-quinone, which depletes GSH | Cell-free system; CHO, U937, THP-1, HL-60, and NB4 cells | 10–200 | Up to 24 hours | [ |
| Indirect effects on antioxidant systems | Inhibition of TrxR | Cell-free system; | 25–100 | 24 hours | [ |
|
| |||||
|
| |||||
| Direct effects as antioxidant | Scavenging of O2 ∙− | U937, K562, HepG2 MCF-7, NHEK cells; RAW 264.7, JB6 cells; Wistar-Kyoto rats | 0–150 | Up to 48 hours | [ |
| Scavenging of | U937, K562 HepG2 MCF-7, NHEK cells | 0–150 | Up to 48 hours | [ | |
| Scavenging of H2O2 | N9 microglial cells, C6 astroglial cells | 25–100 | 0–600 secs | [ | |
| Indirect effects on antioxidant systems | Upregulates glutathione peroxidase and catalase | Rat coronary endothelial cells | 1–100 | 48 hours | [ |
| Upregulates MnSOD | Human coronary endothelial cells | 1–10 | 48 hours | [ | |
| Activates Nrf2 mediated antioxidant response | Normal human epidermal keratinocytes | 20–100 | 16 hours | [ | |
|
| |||||
|
| |||||
| Direct effects as antioxidant | Scavenging of O2 ∙− | Cell-free system; heart homogenate from Wistar rats | 0–200 | 48 hours | [ |
| Scavenging of | Rat L-6 myoblasts | 0–4 | 30 mins | [ | |
| Scavenging of H2O2 | Cell-free system; Rat L-6 myoblasts | 15–45 | 30 mins | [ | |
| Scavenging of ONOO− | [ | ||||
| Scavenging of NO | Cell-free system; G108-15 neuroblastoma-glioma cells | 1–25 | [ | ||
| Scavenging of ROO | Rat L-6 myoblasts | 0–4 | 30 mins | [ | |
| Indirect effects on antioxidant systems | Upregulation of antioxidant enzymes (SOD, CAT, and HO-1) | C6 rat glioma cells; rat cerebellar granule neurons; ECV304 human endothelial cells | 0–100 | Up to 48 hours | [ |
| Replenishment of glutathione pool via upregulation of GR, GPx, and GST | Chick liver | 74 mg/kg | Up to 21 days | [ | |
Direct and in direct effects of Qu, RSV, and Cur on mitochondria-mediated apoptosis.
| Molecule | Effects on mitochondrial-mediated apoptosis | Model used | Doses tested | Time of treatment | References |
|---|---|---|---|---|---|
|
| |||||
| Direct proapoptotic effect | Loss of MMP, followed by release of cyt c | U937 cells; MDA-MB-231 cells | 0–300 | Up to 24 hours | [ |
| Inhibition of ANT and opening of PTP, followed by release of cyt c | Isolated mitochondria from rat kidney | 0–50 | Up to 10 minutes | [ | |
| Depletion of GSH, followed by loss of MMP and cyt c release | U937 cells, human peripheral blood mononuclear cells | 0–100 | Up to 24 hours | [ | |
| Indirect proapoptotic effects | Upregulation of Bax and Bak and downregulation of Bcl-2 and Bcl-xL | HepG2 cells | 0–200 | Up to 72 hours | [ |
| Activation of AMPK1/ASK1/p38 pathway through ROS increase | MCF-7 breast cancer cells; HCT116 and HT-29 cells | 0–400 | Up to 24 hours | [ | |
|
| |||||
|
| |||||
| Direct proapoptotic effects | Loss of MMP, opening of PTP, and release of cyt c | MCF-7, MDA-MB-231 cells, and HepG2 cells | 0–200 | Up to 48 hours | [ |
| Indirect proapoptotic effects | Upregulation of p21 mediated by p53 | Neuroblastoma (SHEP, GIMEN, and LAN5), medulloblastoma (PSFK), glioblastoma (U373MG, A172), melanoma (SK-Mel, Colo38), pancreatic (MiaPaCa2), prostate (LNCaP), and breast carcinoma (MCF-7) cells | 0–100 | Up to 24 hours | [ |
| Downregulation of Bcl-xL, Mcl-1, and Bcl-2 | Ramos and Raji, TIB-196 and CCL-155 B cell lines | 0–200 | Up to 24 hours | [ | |
| Upregulation and oligomerization of Bax | HCT116 cells; F344 rats | 0–100 | 32 hours; three months | [ | |
|
| |||||
|
| |||||
| Direct proapoptotic effects | Increase of O2 ∙−, followed by increase in mitochondrial permeability and release of cyt c | HCT-116 and HT-29 cells | 0–160 | Up to 72 hours | [ |
| PTP opening, followed by mitochondrial swelling and increase in permeability | Isolated mitochondria from rat liver | 0–20 | Up to 15 minutes | [ | |
| Release of cyt c and AIF | T98G, PC3, LNCaP, MDA-MB23, Jurkat cells, and immortalized human fibroblasts | 15–25 | Up to 24 hours | [ | |
| Indirect proapoptotic effects | Upregulation of Bax via a p53-dependent pathway | MCF-7 cells | 10 | Up to 48 hours | [ |
| Upregulation of Bax, Bak, Bim, Bid, and Apaf-1 | HCT-116, PC3, LNCaP, MDA-MB23, Jurkat cells, immortalized human fibroblasts, and embryonic fibroblasts | 0–50 | Up to 72 hours | [ | |
| Downregulation of Bcl-2 and Bcl-XL | HepG2, U266, and MM.1 cells | 0–50 | Up to 16 hours | [ | |
| Damage of mtDNA, which impairs mitochondrial functions | HepG2, HT1080, and HEK293T cells | 0–40 | Up to 24 hours | [ | |